KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Share-based Compensation (2016 - 2025)

Eli Lilly's Share-based Compensation history spans 17 years, with the latest figure at $136.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 4.36% year-over-year to $136.1 million; the TTM value through Dec 2025 reached $626.0 million, down 3.1%, while the annual FY2025 figure was $626.0 million, 3.1% down from the prior year.
  • Share-based Compensation reached $136.1 million in Q4 2025 per LLY's latest filing, down from $151.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $215.6 million in Q3 2023 to a low of $75.3 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $130.7 million, with a median of $132.2 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 153.35% in 2023, then crashed 38.22% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $75.3 million in 2021, then increased by 23.37% to $92.9 million in 2022, then increased by 29.92% to $120.7 million in 2023, then grew by 17.9% to $142.3 million in 2024, then decreased by 4.36% to $136.1 million in 2025.
  • Per Business Quant, the three most recent readings for LLY's Share-based Compensation are $136.1 million (Q4 2025), $151.1 million (Q3 2025), and $185.1 million (Q2 2025).